HealthFinSMEsabout 3 hours ago
SereNeuro Closes Pre-Seed Funding Round
4 min read
SereNeuro Therapeutics announced today the close of its oversubscribed pre-seed financing. The round advances its lead program, SN101, toward Investigational New Drug activities. In September 2026, the company received its first NIH Small Business Innovation Research award to support its second program, SN102.
Level
Hype check
Tap to vote and see what everyone thinks.
